Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
Status:
Terminated
Trial end date:
2018-05-22
Target enrollment:
Participant gender:
Summary
Randomized, Open-Label study to determine the dose, efficacy, safety and pharmacokinetic
profile of ANF-RHO™ with once-per-cycle injection in comparison with Neulasta in Breast
Cancer patients at high risk of developing Chemotherapy-Induced Neutropenia